TAUNS Laboratories, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TAUNS Laboratories, Inc. - overview
Established
1987
Location
-, Shizuoka, Japan
Primary Industry
Medical Devices & Equipment
About
Based in Japan, TAUNS Laboratories, Inc. is engaged in the development and manufacturing of in vitro diagnostic (IVD) products, focusing on rapid and reliable solutions for healthcare environments. Founded in 1987, TAUNS Laboratories, Inc. specializes in IVD products that enhance patient care.
The company operates from its headquarters in Japan, offering innovative diagnostic solutions globally. The founder's history and previous ventures are not publicly detailed. The company has completed 3 deals, with Aizawa Asset Management being a recent investor; financial terms of this investment were not disclosed. TAUNS Laboratories, Inc.
specializes in the development and manufacture of in vitro diagnostic (IVD) products. Their core offerings provide reliable and rapid diagnostic solutions, enhancing patient care and safety. The company’s unique IVD products focus on infectious disease detection, catering to hospitals, clinics, and laboratories. These solutions enable healthcare providers to diagnose conditions promptly, ultimately improving treatment outcomes for patients.
TAUNS's products are marketed primarily in Asia, Europe, and North America, serving a diverse clientele that includes healthcare professionals, laboratories, and hospitals, ensuring broad accessibility to their innovative diagnostic technologies. TAUNS Laboratories generates revenue through direct sales of its diagnostic products to healthcare facilities and laboratories, employing a business-to-business (B2B) transaction model. Revenue is primarily derived from the sales of specific products designed for various diagnostic applications. While specific cost details are not publicly disclosed, the company’s focus on quality and innovation positions its flagship products favorably within the competitive landscape of medical diagnostics, contributing to its ongoing revenue streams.
TAUNS Laboratories, Inc. plans to expand its product line by launching new diagnostic solutions aimed at improving infectious disease detection. The specific release dates for these upcoming products have yet to be announced. The company is also targeting expansion into new markets in Asia and North America by the end of the next fiscal year.
Recent funding from Aizawa Asset Management will support these initiatives, though the exact allocation of these funds remains undisclosed.
Current Investors
Trustar Capital, Aizawa Asset Management
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment
Website
www.tauns.co.jp/
Verticals
Manufacturing, Nanotechnology
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
TAUNS Laboratories, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | CLAIRVO TECHNOLOGIES INC. | - | ||||||||
| IPO | Completed | TAUNS Laboratories, Inc. | - | ||||||||
| Buyout | Completed | TAUNS Laboratories, Inc. | - | ||||||||
| Buyout | Completed | TAUNS Laboratories, Inc. | - |
Displaying 1 - 4 of 4
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.